Major Depressive Disorder Clinical Trials

96 studies are recruiting for major depressive disorder in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Accelerated TMS for Perinatal Depression

   We are studying a treatment for depression called accelerated Transcranial Magnetic Stimulation (TMS) among pregnant and postpartum individuals. TMS is a focal, non-invasive form of brain stimulation that is cleared by the Food and Drug Administration for depression. Typically, traditional TMS invo…

   Stage

   Not phased

   Ages

   18 to 55

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Run by

   Brigham and Women's Hospital

   See if you can join NCT06968390 on ClinicalTrials.gov

2. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

   This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Bryant, Arkansas

   Locations

   19 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07105111 on ClinicalTrials.gov

3. Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders

   Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG). Patients will be studied over on…

   Stage

   Phase 2

   Ages

   8 to 65

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Locations

   2 in total

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT00018057 on ClinicalTrials.gov

4. Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

   Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect. Objectiv…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT03065335 on ClinicalTrials.gov

5. Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

   The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation …

   Stage

   Phase 1

   Ages

   21 to 45

   Site

   Wells Medicine, Houston, Texas

   Locations

   2 in total

   Run by

   Texas A&M University

   See if you can join NCT06480201 on ClinicalTrials.gov

6. Near Infrared Spectroscopy (NIRS) for Assessment of Depression

   Develop a NIRSIT testing protocol that can be administered in the diagnostic setting and reliably distinguishes the symptoms and severity of depression, with the help of repeated measure (up to five visits per subject) comparison of patients being treated for Major Depressive Disorder with control,…

   Stage

   Not phased

   Ages

   18 and older

   Site

   San Francisco Veterans Affairs Medical Center, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT04061148 on ClinicalTrials.gov

7. Defining Neurobiological Links Between Substance Use and Mental Illness

   Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting comp…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   National Institute on Drug Abuse, Baltimore, Maryland

   Run by

   National Institute on Drug Abuse (NIDA)

   See if you can join NCT05538910 on ClinicalTrials.gov

8. Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

   Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work. A drug that blocks these receptors might affect how it works. Objective: To see if the antidepressant …

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT03973268 on ClinicalTrials.gov

9. A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

   X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

   Stage

   Phase 3

   Ages

   18 to 74

   Site

   University of Alabama at Birmingham, Huntsville Regional Medical Campus, Huntsville, Alabama

   Locations

   50 in total

   Run by

   Xenon Pharmaceuticals Inc.

   See if you can join NCT07076407 on ClinicalTrials.gov

10. Decoding and Modulating Affective Brain States

    The research study is being conducted to study brain patterns of negative emotion and develop personalized brain stimulation protocols to disrupt these patterns with transcranial magnetic stimulation (TMS). First, the investigators will use functional Magnetic Resonance Imaging (fMRI) data to gener…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    University of Pennsylvania

    See if you can join NCT05437705 on ClinicalTrials.gov

11. Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression

    Anhedonia, the inability to seek-out and experience pleasure, is a common symptom in depression that predicts treatment-resistance and is sometimes exacerbated by first-line antidepressants. In our previous research, we found that anhedonia decreases goal-directed behavior and its related neural ac…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Florida State University, Tallahassee, Florida

    Run by

    Florida State University

    See if you can join NCT06132581 on ClinicalTrials.gov

12. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

    This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    University of Alabama at Birmingham, Huntsville, Alabama

    Locations

    69 in total

    Run by

    Intra-Cellular Therapies, Inc.

    See if you can join NCT05850689 on ClinicalTrials.gov

13. 5-HTP and Creatine for Depression R33 Phase

    This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 wee…

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    University of Utah Department of Psychiatry, Salt Lake City, Utah

    Run by

    University of Utah

    See if you can join NCT05895747 on ClinicalTrials.gov

14. Positive Processes and Transition to Health (PATH)

    The R33 will be a randomized controlled trial to replicate changes in the targets (unproductive processing, avoidance, reward deficits) from the R61 phase in a larger sample of 135 participants who have experienced a destabilizing life event involving profound loss or threat, report persistent stre…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    University of Delaware, Newark, Delaware

    Locations

    3 in total

    Run by

    Case Western Reserve University

    See if you can join NCT06093906 on ClinicalTrials.gov

15. Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents

    This is a single-site open-label clinical trial of fMRI-guided accelerated intermittent theta burst stimulation. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS)-is effect…

    Stage

    Not phased

    Ages

    13 to 20

    Site

    Dell Medical School at University of Texas at Austin, Austin, Texas

    Run by

    University of Texas at Austin

    See if you can join NCT06523439 on ClinicalTrials.gov

16. Enhancing Veteran-Clinical Collaboration in VA PRRCs

    Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives. Although traditional treatments tend to focus on symptom remission, Veterans prioritize a range of treatment goals, including…

    Stage

    Not phased

    Ages

    18 and older

    Site

    New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico

    Locations

    3 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT06898879 on ClinicalTrials.gov

17. Natural History of Depression, Bipolar Disorder and Suicide Risk

    Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for…

    Stage

    Not phased

    Ages

    18 to 120

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Mental Health (NIMH)

    See if you can join NCT06462196 on ClinicalTrials.gov

18. The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

    This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.

    Stage

    Phase 3

    Ages

    18 to 55

    Site

    Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts

    Run by

    Sharmin Ghaznavi

    See if you can join NCT06247839 on ClinicalTrials.gov

19. Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy

    This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of …

    Stage

    Phase 2

    Ages

    18 to 90

    Site

    Pine Rest Christian Mental Health Services, Grand Rapids, Michigan

    Run by

    Michigan State University

    See if you can join NCT06529029 on ClinicalTrials.gov

20. Pain and Major Depressive Disorder

    This study will examine the effects of brain stimulation on pain symptoms associated with Major depressive disorder. This study will enroll 54 Subjects. Study subjects will be asked to complete surveys about their mood and well-being, 2 blood draws, 2 MRIs, 3 electroencephalograms, and receive 30 t…

    Stage

    Not phased

    Ages

    18 to 75

    Site

    UCLA Semel Institute, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT04556890 on ClinicalTrials.gov

21. NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Neurocrine Clinical Site, Huntsville, Alabama

    Locations

    39 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT06911112 on ClinicalTrials.gov

22. Remote Evaluation and Alerting for Collaborative Health (REACH) in Depression

    Researchers hope to see if the data smartphones collect continuously can be used to predict if patient's depression symptoms will return. They will do this by collecting data from patient's smartphones and comparing it to their depression symptoms. If this method is successful, researchers could de…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dartmouth College, Hanover, New Hampshire

    Locations

    2 in total

    Run by

    Dartmouth-Hitchcock Medical Center

    See if you can join NCT07174557 on ClinicalTrials.gov

23. NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Neurocrine Clinical Site, Chino, California

    Locations

    35 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT06963021 on ClinicalTrials.gov

24. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

    Stage

    Phase 3

    Ages

    18 to 74

    Site

    Preferred Research Partners, Inc., Little Rock, Arkansas

    Locations

    30 in total

    Run by

    Definium Therapeutics US, Inc.

    See if you can join NCT07592689 on ClinicalTrials.gov

25. Closed-Loop Deep Brain Stimulation for Major Depression

    Neurons are specialized types of cells that are responsible for carrying out the functions of the brain. Neurons communicate with electrical signals. In diseases such as major depression this electrical communication can go awry. One way to change brain function is using electrical stimulation to h…

    Stage

    Not phased

    Ages

    22 to 70

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Andrew Krystal

    See if you can join NCT04004169 on ClinicalTrials.gov